1 |
DEVLIN C M, SIMMS M S, MAITLAND N J. Benign prostatic hyperplasia-what do we know?[J]. BJU Int, 2021, 127(4): 389-399.
|
2 |
LERNER L B, MCVARY K T, BARRY M J, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: aua guideline part Ⅱ-surgical evaluation and treatment[J]. J Urol, 2021, 206(4): 818-826.
|
3 |
FRANCO J V, TRIVISONNO L, SGARBOSSA N J, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement[J]. Cochrane Database Syst Rev, 2023, 6(6): CD001423.
|
4 |
ISAACS J T. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention[J]. Prostate Suppl, 1990, 3: 1-7.
|
5 |
SEBASTIANELLI A, RUSSO G I, KAPLAN S A, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine[J]. Int J Urol, 2018, 25(3): 196-205.
|
6 |
CINDOLO L, PIROZZI L, SOUNTOULIDES P, et al.Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?[J]. BMC Urol, 2015, 15: 96.
|
7 |
GUPTA R, TRIVEDI S, VADDI S P, et al. Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population[J]. Urol Ann, 2023, 15(2): 138-147.
|
8 |
MCVARY K T. A review of combination therapy in patients with benign prostatic hyperplasia[J]. Clin Ther, 2007, 29(3): 387-398.
|
9 |
CORNU J N, ZANTEK P, BURTT G, et al. Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis[J]. Eur Urol, 2023, 83(6): 534-547.
|
10 |
HU Y Y, DONG X C, WANG G C, et al. Five-year follow-up study of transurethral plasmakinetic resection of the prostate for benign prostatic hyperplasia[J]. J Endourol, 2016, 30(1): 97-101.
|
11 |
REICH O, GRATZKE C, BACHMANN A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10, 654 patients[J].J Urol, 2008,180(1): 246-249.
|
12 |
GU M, CHEN Y B, ZHAN M, et al. Comparison of thermal injury depth of the prostate between plasma kinetic electrode, holmium laser, green light laser and Nd: YAG laser[J]. Int Urol Nephrol, 2021, 53(5): 863-867.
|
13 |
XIAO K W, MA Y C, LUO Z M, et al. Network meta-analysis of the treatment safety and efficacy of different energy systems in prostate vaporization[J]. Lasers Med Sci, 2023, 38(1): 150.
|
14 |
NADLER S B, HIDALGO J H, BLOCH T. Prediction of blood volume in normal human adults[J]. Surgery, 1962, 51(2): 224-232.
|
15 |
FU X, LIU J M, LIU D Q, et al. Glucose-regulated protein 78 modulates cell growth, epithelial-mesenchymal transition, and oxidative stress in the hyperplastic prostate[J].Cell Death Dis,2022,13(1): 78.
|
16 |
WANG K Y, WU J H. Regulatory effect of NF-κB on prostatic hyperplasia: progress in researches[J]. Zhonghua Nan Ke Xue, 2021, 27(11): 1025-1029.
|
17 |
BRENNEN W N, ISAACS J T. Mesenchymal stem cells and the embryonic reawakening theory of BPH[J]. Nat Rev Urol, 2018, 15(11): 703-715.
|
18 |
EL-SAHAR A E, BEKHIT N, EISSA N M, et al. Targeting HMGB1/PI3K/Akt and NF-κB/Nrf-2 signaling pathways by vildagliptin mitigates testosterone-induced benign prostate hyperplasia in rats[J]. Life Sci, 2023, 322: 121645.
|
19 |
MOBLEY D, FEIBUS A, BAUM N. Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment[J]. Postgrad Med, 2015, 127(3): 301-307.
|
20 |
FRANCO J V, GAREGNANI L, ESCOBAR LIQUITAY C M, et al. Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia[J]. Cochrane Database Syst Rev, 2021, 6(6): CD004135.
|
21 |
彭 伟, 吴海霞, 桂定文, 等. 评价经尿道前列腺双极等离子电切术与前列腺电切术治疗良性前列腺增生的临床效果及其安全性[J]. 中国性科学, 2017, 26(5): 24-27.
|
22 |
KARADENIZ M S, BAYAZIT E, AKSOY O, et al. Bipolar versus monopolar resection of benign prostate hyperplasia: a comparison of plasma electrolytes, hemoglobin and TUR syndrome[J]. SpringerPlus, 2016, 5(1): 1739.
|